Latest Headlines

Latest Headlines

Astellas buys out Maxygen stake in JV for $76M

Astellas Pharma has exercised a buy-out option to acquire all of Maxygen's ownership interest in Perseid Therapeutics, a protein joint venture between the two companies. They formed the JV back in

Maxygen shakes up its executive ranks after spinout

Just days after transferring $10 million in cash and all its work on protein pharmaceuticals to a new joint venture with Astellas Pharma, Maxygen (MAXY) has announced a restructuring that will see

Maxygen axes staff, cuts expenses, seeks partner

Maxygen is joining the list of biotech companies hunkering down in an effort to hold on to cash. The developer says it will cut close to a third of its payroll and reduce staff to 65 as it hunts for

Maxygen inks $180M deal with Astellas

Maxygen is pocketing a $10 million upfront fee from Japan's Astellas for marketing rights to its Maxy-4 therapies--a preclinical program focused on developing a next-generation CTLA4-Ig protein for

Maxygen inks $120M deal for hemophilia program

Maxygen has inked a deal to sell its hemophilia drug development program to Bayer for $90 million upfront and up to $30 million in milestone payments. The program is still in the preclinical stage,

Mpex in pact with GSK; Biogen favored in Icahn spat; Maxygen shares slide on threatened patent dispute;

> Mpex has inked a collaboration deal with GlaxoSmithKline. The collaboration provides GlaxoSmithKline access to Mpex's novel efflux pump inhibitors and related technology for use in combination

C&L: Lundbeck CEO resigns early

Denmark's H Lundbeck announced that its president and chief executive Claus Braestrup has resigned earlier than expected. Critical Therapeutics announced that Frank Thomas will resign as president

Maxygen, Sanofi Pasteur ink $24.5M vaccine deal

Maxygen has agreed to transfer a portfolio of preclinical dengue antigens to Sanofi Pasteur for use developing a second generation vaccine. Maxygen stands to gain up to $24.5 million in the deal. The

SPOTLIGHT: Maxygen closes Denmark facility

Maxygen is shutting down its Denmark facility--which has largely focused on preclinical activities--and is adding 25 staffers to its Redwood City headquarters as it restructures.

Roche halts Phase I trial

Roche has halted a trial of MAXY-alpha, also known as R7025, due to an unanticipated reduction of the pharmacodynamic and pharmacokinetic effects in patients who received the drug. Roche and